228 related articles for article (PubMed ID: 31923568)
1. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
[TBL] [Abstract][Full Text] [Related]
2. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
[TBL] [Abstract][Full Text] [Related]
3. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
[TBL] [Abstract][Full Text] [Related]
4. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
[TBL] [Abstract][Full Text] [Related]
5. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin/tazobactam-resistant, cephalosporin-susceptible
Edwards T; Heinz E; van Aartsen J; Howard A; Roberts P; Corless C; Fraser AJ; Williams CT; Bulgasim I; Cuevas LE; Parry CM; Roberts AP; Adams ER; Mason J; Hubbard ATM
Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35404783
[TBL] [Abstract][Full Text] [Related]
7. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Lee J; Oh CE; Choi EH; Lee HJ
Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
[TBL] [Abstract][Full Text] [Related]
8. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
[TBL] [Abstract][Full Text] [Related]
10. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
[TBL] [Abstract][Full Text] [Related]
11. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
12.
Stainton SM; Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28607019
[TBL] [Abstract][Full Text] [Related]
13. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
[TBL] [Abstract][Full Text] [Related]
14. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
Rice LB; Carias LL; Bonomo RA; Shlaes DM
J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Karlsson IM; Ge Y; Giske CG
Diagn Microbiol Infect Dis; 2011 May; 70(1):137-41. PubMed ID: 21513849
[TBL] [Abstract][Full Text] [Related]
17. β-lactam resistance associated with β-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae.
Khalifa SM; Abd El-Aziz AM; Hassan R; Abdelmegeed ES
PLoS One; 2021; 16(5):e0251594. PubMed ID: 34014957
[TBL] [Abstract][Full Text] [Related]
18. Trends in Expanded-Spectrum Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae among Dutch Clinical Isolates, from 2008 to 2012.
van der Steen M; Leenstra T; Kluytmans JA; van der Bij AK;
PLoS One; 2015; 10(9):e0138088. PubMed ID: 26381746
[TBL] [Abstract][Full Text] [Related]
19. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
20. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
Moland ES; Sanders CC; Thomson KS
J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
